Capstan Therapeutics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 34)
Capstan Therapeutics logo

Capstan Therapeutics

EmergingLife Sciences & BioTech

In Vivo RNA Cell Engineering & Gene Therapy

Capstan Therapeutics develops in vivo RNA-based therapies using targeted lipid nanoparticles to engineer immune cells inside the body without ex vivo manufacturing; raised $165M Series A in 2022; targeting oncology, fibrosis, and autoimmune diseases.

AI VisibilityBeta
Overall Score
D34
Category Rank
#164 of 198
AI Consensus
89%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
33
Gemini
35

About

Capstan Therapeutics is a biopharmaceutical company founded in 2021 and headquartered in Philadelphia, Pennsylvania, with scientific co-founders including Drew Weissman (2023 Nobel Prize in Medicine laureate for mRNA technology) and Carl June (pioneer of CAR-T cell therapy). The company is developing a novel class of in vivo RNA-based medicines that use targeted lipid nanoparticles (LNPs) to deliver genetic instructions directly into specific immune cells inside the patient's body — enabling the creation of therapeutic immune cells (similar to CAR-T cells) without the costly and time-consuming ex vivo manufacturing process that currently requires extracting, engineering, and re-infusing a patient's cells outside the body.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

34
Overall Score
74
#164
Category Rank
#11
89
AI Consensus
68
stable
Trend
stable
36
ChatGPT
71
33
Perplexity
68
35
Gemini
80
38
Claude
77
35
Grok
69

Key Details

Category
In Vivo RNA Cell Engineering & Gene Therapy
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.